Management of dyslipidemia – review of the ESC/EAS guidelines 2011 Review article
Article Sidebar
Main Article Content
Abstract
Dyslipidemia is one of a major risk factor for developing cardiovascular disease such as coronary artery disease, stroke and peripheral artery disease. The most recent guidelines of The European Society of Cardiology and The European Atherosclerosis Society (2011) summarize the current state of knowledge and describe strategy for prevention and treatment of patients with dyslipidemia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Cybulska B., Szostak W.B., Kłosiewicz-Latoszek L.: Zapobieganie chorobom układu krążenia. W: Choroby wewnętrzne: stan wiedzy na rok 2011. Szczeklik A. (red.). Medycyna Praktyczna, Kraków 2011: 149.
3. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007, 28(19): 2375-414.
4. Wanner C., Krane V., Marz W. et al.: German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353(3): 238-248.
5. Fellström B.C., Jardine A.G., Schmieder R.E. et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009, 360(14): 1395-1407. 6. Baigent C., Landray M.J., Reith C. et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784): 2181-92.